SCHEMBL5759507

SCHEMBL5759507

O=c1cc(C(F)(F)F)c2cc(Cc3ccc(S(=O)(=O)NCc4cc(C(F)(F)F)ccc4F)cc3)ccc2[nH]1

nearest known ligand 0.42

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.42
CYP19A1 P11511 1/20 0.41
AR P10275 16/20 0.41
CNR1 P21554 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5762495 0.92 POLB (0.44) POLBARCNR1
SCHEMBL6022249 0.91 POLB (0.46) POLBCYP19A1AR
SCHEMBL5760193 0.85 POLB (0.46) POLBCYP19A1AR
SCHEMBL5762317 0.84 POLB (0.42) POLBARCNR1
SCHEMBL5761506 0.84 MAPT (0.46) POLBARCNR1
SCHEMBL5860298 0.84 POLB (0.48) POLBAR
SCHEMBL5759940 0.84 POLB (0.62) POLBCYP19A1AR
SCHEMBL5759341 0.83 POLB (0.47) POLBAR
SCHEMBL5760272 0.83 POLB (0.43) POLBCYP19A1ARCNR1
SCHEMBL6022693 0.82 POLB (0.46) POLBAR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7098340-B2 Quinoline/chromene derivatives as androgen antagonist WARNER LAMBERT COMPANY LLC (US) 2006-08-29 US claimed
EP-1633732-A1 BENZYL SULFONAMIDE DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY (US) 2006-03-15 EP claimed
WO-2004101544-A1 BENZYL SULFONAMIDE DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY LLC (US) 2004-11-25 WO claimed
US-7098340-B2 Quinoline/chromene derivatives as androgen antagonist WARNER LAMBERT COMPANY LLC (US) 2006-08-29 US disclosed
US-20050137228-A1 Benzyl sulfonamide derivatives DU DANIEL Y (US) 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137228-A1 Benzyl sulfonamide derivatives AR, SHBG, BRDT POLB 4183/4885CYP19A1 5/4885AR 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.